Fermenta BiotechQ3 FY21

Fermenta Biotech Q3 FY21 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹465.5P/E: 29.5Market Cap: ₹1.4K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2
  • Human Vitamin D3 business volume growth has been strong, with a 61% increase in volumes reported for nine months FY21, driven primarily by COVID-related demand and new customer additions.
  • Price increase in human Vitamin D3 was modest (~6%), with most growth volume-driven.
  • Animal feed segment experienced a de-growth due to COVID impact on consumption but expected to rebound as normalcy returns.
  • Capacity expansion underway: Human Vitamin D3 capacity to increase by ~25% with a new plant commissioning expected to start contributing next quarter.
  • US market expansion via acquisition of AGD Nutrition aims to significantly increase market share, with potential revenue growth through synergy and investments over next 1-2 years.
  • Nutritional product portfolio expected to expand with new products like Vitamin AD2 formulations and Vitamin K1 planned for launch.
  • Long-term company outlook sees sustained demand for Vitamin D3 due to its immunity benefits, beyond the COVID spike, though growth rate may normalize.

See what Fermenta Biotech management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • There is no explicit mention of any current or planned fundraising through debt or equity in the transcript.
  • The management discussed investments planned in their acquired US entity (AGD Nutrition) of approximately $1-2 million over the next year for capacity expansions and partnerships, but this appears to be funded internally.
  • The company is focusing on monetizing real estate assets as a potential source of funds; however, no timelines or commitments on proceeds or equity/debt issuance are given.
  • The company emphasizes strengthening operations and capacity utilization rather than raising external capital at this time.
  • No mention of issuing new equity or taking on additional debt financing was made during the call or in the provided transcript pages.

See what Fermenta Biotech management said on order book — free account, 30 seconds.

Capex plans

Yes
  • The company is commissioning a new plant this quarter to increase human Vitamin D3 capacity by around 25% next year.
  • They are investing in backward integration for cholesterol manufacturing from fish oil, expecting EBITDA contribution to start soon with projected Rs.14-15 crore annual EBITDA.
  • Post-acquisition of AGD Nutrition, they anticipate investing an additional 1-2 million USD in the acquired entity over the next year for developing value-added products in human Vitamin D3.
  • Plans to enter the nutrition space beyond Vitamin D3, including Vitamin K1 (plant ready this year) and vitamin AD2 formulations targeted for launch early next year.
  • Intends to invest in premix plants to offer mixed vitamin and mineral formulations in the B2B nutrition segment.
  • No further capital investment planned in real estate; focus is on monetizing existing assets without timeline commitment.

Track Fermenta Biotech — get its next earnings analysis in your feed

How does Fermenta Biotech rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisFermenta Biotech
Rev 2Mar 3

How does Fermenta Biotech rank in Pharmaceuticals & Biotechnology?

Compare Fermenta Biotech against every Pharmaceuticals & Biotechnology company (Q3 FY21) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →